Mylan and Biocon jointly announced earlier this month that their biosimilar insulin glargine, sold as Semglee and referencing Lantus, has launched in the United Kingdom.
Mylan and Biocon jointly announced earlier this month that their biosimilar insulin glargine, sold as Semglee and referencing Lantus, has launched in the United Kingdom.
Semglee is approved in the European Union as a once-daily 100 units/mL dose, long-acting basal insulin indicated for the treatment of diabetes mellitus in adults, adolescents, and children aged 2 years old and above.
“Insulin glargine biosimilars play a key role in the challenges faced by the [National Health Service, NHS] and offer a better value option by being able to deliver increased affordability compared with the originator insulin glargine while still offering comparable safety, efficacy, and tolerability,” said Jean-Yves Brault, Mylan’s UK country manager.
Nearly 1 in 17 people living in the UK are believed to have diabetes, and the NHS currently spends around 10% of its entire budget on managing the disease, highlighting the need for lower-cost options.
“The UK launch of Semglee, a biosimilar insulin glargine co-developed by Mylan and Biocon, is a reflection of our long-standing commitment to increasing insulin access for diabetes patients through the development of high quality biosimilars,” commented Paul Thomas, chief commercial officer at Biocon.
However, though approved in the European Union, the follow-on insulin glargine has yet to reach approval in the United States, where it is the subject of ongoing patent infringement litigation. Sanofi, maker of reference insulin glargine Lantus, filed suit against Mylan in October 2017 alleging that Mylan infringed upon 18 patents and asked a federal court in New Jersey to intervene in any launch efforts.
The lawsuit has not been the only challenge to bringing the follow-on insulin to the US market, as it received a Complete Response Letter (CRL) from the FDA in June 2018, citing production problems at the Malaysia plant responsible for producing the product.
Mylan and Biocon have partnered on the development and marketing of various biosimilar and insulin products. Mylan owns the exclusive commercialization rights for the insulin glargine follow-on/biosimilar in the United States, Canada, Australia, New Zealand, the European Union, and European Free Trade Association countries. Conversely, Biocon has exclusive commercialization rights for Japan and a few other emerging markets, as well as co-exclusive commercialization rights jointly with Mylan in the rest of the world.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international regognition procedure under the Medicines and Healthcare products Regulatory Agency (MHRA) could expand biosimilar access within the United kingdom, in his latest column.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
FDA Green Lights Second Tocilizumab Biosimilar
March 7th 2024The FDA has approved Fresenius Kabi's tocilizumab biosimilar (Tyenne; tocilizumab-aazg), making it the second tocilizumab biosimilar overall and first tocilizumab biosimilar to be approved with both intravenous and subcutaneous administration options.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.